<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103376</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000406013</org_study_id>
    <secondary_id>MUSC-031218</secondary_id>
    <secondary_id>MUSC-HR-11357</secondary_id>
    <nct_id>NCT00103376</nct_id>
  </id_info>
  <brief_title>Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer</brief_title>
  <official_title>VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such
      as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making
      androgens. Giving bortezomib with hormone therapy may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving bortezomib with or without hormone
      therapy works in treating patients with relapsed prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Accrual
  </why_stopped>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific Antigen (PSA) Response</measure>
    <time_frame>3 months after the start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>From on study until time of PSA progression for up to two years</time_frame>
    <description>PSA progression is defined as a PSA increase of 50% over the nadir CR or CR/PR value on three successive PSA measurements two months apart to a value of &gt;= 1.0 ng/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Experienced an Adverse Event by CTCAE v. 2.0</measure>
    <time_frame>From start of treatment until end of study, up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Interval</measure>
    <time_frame>3 months after combined treatment</time_frame>
    <description>This will only be analyzed if sample size warrants the analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: Velcade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Part B (Velcade + antiandrogen). If the patient has a partial response or stable disease, he will start Part B after at least a 7-day break.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will start Part B after completing Part A or may be enrolled to part B only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.
Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break</description>
    <arm_group_label>Part A: Velcade</arm_group_label>
    <arm_group_label>Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist</arm_group_label>
    <other_name>bortezomib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LH-RH Agonist</intervention_name>
    <description>given as a 3 month depo-injection</description>
    <arm_group_label>Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androgen Receptor Antagonists</intervention_name>
    <description>given orally daily for 3 months</description>
    <arm_group_label>Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Relapsed disease after definitive local therapy, as documented only by a rise in
             prostate-specific antigen (PSA)

               -  Experienced PSA relapse after definitive local therapy

               -  Rising PSA (≥ 1.0 ng/mL after nadir &lt; 1.0 ng/mL)

                    -  PSA increase of ≥ 0.3 ng/mL (increase occurred between 2 separate
                       measurements taken ≥ 4 weeks apart)

               -  The first of these two PSA values must rise above a previously recorded
                  post-therapy nadir value

          -  Ineligible for curative therapy

          -  No clinical evidence of local recurrence (i.e., palpable induration or mass in the
             prostatic fossa) other than PSA elevation

          -  No evidence of palpable disease in the prostatic bed

          -  No metastatic disease (M0)

               -  No non-nodal (&gt; N1) metastasis

               -  No evidence of osseous metastasis on bone scan within the past 28 days

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  At least 1 year

        Hematopoietic

          -  Platelet count ≥ 30,000/mm^3

          -  Absolute neutrophil count ≥ 1,000/mm^3

        Hepatic

          -  No known hepatitis B or C positivity

        Renal

          -  Creatinine clearance ≥ 30 mL/min

        Immunologic

          -  No known human T-cell lymphotropic virus positivity

          -  No hypersensitivity to bortezomib, boron, or mannitol

          -  No known HIV 1 or 2 positivity

          -  No active, ongoing bacterial, viral, or fungal infection

        Other

          -  Fertile patients must use effective contraception

          -  No peripheral neuropathy ≥ grade 2

          -  No other disease, condition, or social or geographic constraint that would preclude
             study participation

          -  No other malignancy within the past 5 years except basal cell or squamous cell skin
             cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy

          -  See Disease Characteristics

          -  At least 6 months since prior hormonal therapy combined with radiation therapy as
             definitive therapy

          -  Neoadjuvant hormonal therapy prior to definitive therapy (e.g., surgery, radiation
             therapy, brachytherapy, or cryoablation) allowed

          -  No other concurrent hormonal therapy

        Radiotherapy

          -  See Disease Characteristics

          -  More than 12 months since prior radioactive seed therapy

          -  No concurrent radiotherapy

        Surgery

          -  See Disease Characteristics

          -  More than 4 weeks since prior surgery

          -  No concurrent surgery

        Other

          -  No concurrent second-line herbal preparations, including PC-SPES

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S. Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Leone</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina, Hollings Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gibbs Regional Cancer Center at Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 7, 2005</study_first_submitted>
  <study_first_submitted_qc>February 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2005</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>October 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Androgen Receptor Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A Only: Velcade</title>
          <description>Patients who were enrolled to Part A but did not move on to Part B</description>
        </group>
        <group group_id="P2">
          <title>Part B (Velcade+LH-RH Antagonist+Adrogen Receptor)</title>
          <description>Patients who were enrolled only to part B.</description>
        </group>
        <group group_id="P3">
          <title>Part A + Part B</title>
          <description>Patients who completed part A and moved in to Part B.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A Only: Velcade</title>
          <description>Patients who were enrolled to Part A but did not move on to Part B.</description>
        </group>
        <group group_id="B2">
          <title>Part B (Velcade + LH-RH Antagonist+Androgen Receptro</title>
          <description>Patients who were enrolled only to part B</description>
        </group>
        <group group_id="B3">
          <title>Part A + Part B</title>
          <description>Patients who completed part A and moved in to part B.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prostate-specific Antigen (PSA) Response</title>
        <time_frame>3 months after the start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A: Velcade</title>
            <description>Patients who were enrolled to Part A but did not move on to Part B</description>
          </group>
          <group group_id="O2">
            <title>Part B: (Velcade+LH-RH Antagonist+Adrogen Receptor)</title>
            <description>Patients who were enrolled only to part B.</description>
          </group>
          <group group_id="O3">
            <title>Part A + Part B</title>
            <description>Patients who completed part A and moved in to Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-specific Antigen (PSA) Response</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to PSA Progression</title>
        <description>PSA progression is defined as a PSA increase of 50% over the nadir CR or CR/PR value on three successive PSA measurements two months apart to a value of &gt;= 1.0 ng/ml.</description>
        <time_frame>From on study until time of PSA progression for up to two years</time_frame>
        <population>Only patients with a CR were included in the analysis. No patients in Part A had a complete response. Time to progression for Part B only and Part A+Part B was calculated together. The information for the confidence interval is not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A Only: Velcade</title>
            <description>Patients who were enrolled to Part A but did not move on to Part B.</description>
          </group>
          <group group_id="O2">
            <title>Part B and Part A + Part B</title>
            <description>Patients who were enrolled to Part B (Velcade + LH-RH Antagonist+Androgen Receptor) and Part A (Velcade only) + Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression</title>
          <description>PSA progression is defined as a PSA increase of 50% over the nadir CR or CR/PR value on three successive PSA measurements two months apart to a value of &gt;= 1.0 ng/ml.</description>
          <population>Only patients with a CR were included in the analysis. No patients in Part A had a complete response. Time to progression for Part B only and Part A+Part B was calculated together. The information for the confidence interval is not available.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.49" lower_limit="3.91" upper_limit="NA">NA is included to represent the value &quot;infinity&quot;</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Experienced an Adverse Event by CTCAE v. 2.0</title>
        <time_frame>From start of treatment until end of study, up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A Only: Velcade</title>
            <description>Patients who were enrolled to Part A but did not move on to Part B</description>
          </group>
          <group group_id="O2">
            <title>Part B (Velcade+Lh-RH Antagonist+ Androgen Receptor)</title>
            <description>patients who were enrolled only to Part B.</description>
          </group>
          <group group_id="O3">
            <title>Part A + Part B</title>
            <description>Patients who completed Part A and moved in to Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced an Adverse Event by CTCAE v. 2.0</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Interval</title>
        <description>This will only be analyzed if sample size warrants the analysis.</description>
        <time_frame>3 months after combined treatment</time_frame>
        <population>data was not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade and Hormonal Therapy</title>
            <description>Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Velcade + Antiandrogen therapy. If the patient has a partial response or stable disease, he will start Velcade+antiandrogen after at least a 7-day break.
After 3 months on Part B, if the patient has a complete response, he will come off study. Patients with a partial response or stable disease will repeat part B. Patients with progressive disease will come off study.
Velcade: Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.
Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break
LH-RH Agonist: given as a 3 month depo-injection
Androgen Receptor Antagonists: given orally daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Interval</title>
          <description>This will only be analyzed if sample size warrants the analysis.</description>
          <population>data was not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from start of treatment until end of study visit, about 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A: Velcade Only</title>
          <description>Patients who were enrolled to Part A but did not move on to Part B</description>
        </group>
        <group group_id="E2">
          <title>Part B (Velcade+LH-RH Antagonist+Adrogen Receptor)</title>
          <description>Patients who were enrolled only to part B.</description>
        </group>
        <group group_id="E3">
          <title>Part A + Part B</title>
          <description>Patients who completed part A and moved in to Part B.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kate Anderton</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-2708</phone>
      <email>anderton@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

